Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) an Israel-based pharmaceutical technology company, announced on Friday that it has added Dr Joseph V. Pergolizzi, Jr to its Scientific Advisory Board (SAB).
In the new role, Dr Pergolizzi is to concentrate on promoting pharmaceutical human product R&D and FDA filing, as outlined in his Advisory Board member services agreement.
Dr Pergolizzi has served in various C-level positions in private and public companies. He is a senior partner at Naples Anesthesia and Pain Associates and held the position of chief operating officer at NEMA Research Inc. He serves as a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics and a consultant to the National Pain Foundation board of directors. He is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He has worked as a part-time adjunct assistant professor in the Department of Medicine at the Johns Hopkins University School of Medicine.
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline